Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs

References

• Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13(3):129–134.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab. 2003;4(5):393–398.
   PubMed Web of Science ®Google Scholar
• Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008;4(7):923–939.
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm. 2009;6(1):19–28.
   PubMed Web of Science ®Google Scholar
• Takano J, Maeda K, Bolger MB, et al. The prediction of the relative importance of CYP3A/P-glycoprotein to the nonlinear intestinal absorption of drugs by advanced compartmental absorption and transit models. Drug Metab Dispos. 2016;44(11):1808–1818.
   PubMed Web of Science ®Google Scholar
• Gurjar R, Chan CYS, Curley P, et al. Inhibitory effects of commonly used excipients on P-glycoprotein in vitro. Mol Pharm. 2018;15(11):4835–4842.
   PubMedGoogle Scholar
• Murakami T, Bodor E, Bodor N. Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opin Drug Metab Toxicol. 2020;16(1):59–78.
   PubMed Web of Science ®Google Scholar
• Gebert A, Rothkötter AG, Pabst R. M cells in Peyer’s patches of the intestine. Int Rev Cytol. 1996;167:91–159.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23.
   PubMed Web of Science ®Google Scholar
• Guzmán HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96(10):2686–2702.
   PubMed Web of Science ®Google Scholar
• Brewster ME, Vandecruys R, Verreck G, et al. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie. 2008;63(3):217–220.
   PubMed Web of Science ®Google Scholar
• Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549–2572.
   PubMed Web of Science ®Google Scholar
• Bevernage J, Brouwers J, Brewster ME, et al. Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int J Pharm. 2013;453(1):25–35.
   PubMed Web of Science ®Google Scholar
• Mai Y, Dou L, Murdan S, et al. An animal’s sex influences the effects of the excipient PEG 400 on the intestinal P-gp protein and mRNA levels, which has implications for oral drug absorption. Eur J Pharm Sci. 2018;120:53–60.
   PubMed Web of Science ®Google Scholar
• Harwood MD, Zhang M, Pathak SM, et al. The regional-specific relative and absolute expression of gut transporters in adult Caucasians: a meta-analysis. Drug Metab Dispos. 2019;47(8):854–864.
   PubMed Web of Science ®Google Scholar
• Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003;20(10):1595–1599.
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283(3):1552–1562.
   PubMed Web of Science ®Google Scholar
• Evers R, Piquette-Miller M, Polli JW, et al. Disease-associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the international transporter consortium. Clin Pharmacol Ther. 2018;104(5):900–915.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40(3):159–168.
   PubMed Web of Science ®Google Scholar
• Berggren S, Gall C, Wollnitz N, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm. 2007;4(2):252–257.
   PubMedGoogle Scholar
• Von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75(3):172–183.
   PubMed Web of Science ®Google Scholar
• FDA: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system guidance for industry; 2017. https://www.fda.gov/media/70963/download
   Google Scholar
• Varma MVS, Khandavilli S, Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm. 2005;2(1):12–21.
   PubMedGoogle Scholar
• Varma MV, Steyn SJ, Allerton C, et al. Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS). Pharm Res. 2015;32(12):3785–3802.
   PubMed Web of Science ®Google Scholar
• Ghadi R, Dand N. BCS class IV drugs: highly notorious candidates for formulation development. J Control Release. 2017;248:71–95.
   PubMed Web of Science ®Google Scholar
• Heimbach T, Oh DM, Li LY, et al. Absorption rate limit considerations for oral phosphate prodrugs. Pharm Res. 2003;20(6):848–856.
   PubMed Web of Science ®Google Scholar
• Murakami T. Absorption sites of orally administered drugs in the small intestine. Expert Opin Drug Discov. 2017;12(12):1219–1232.
   PubMed Web of Science ®Google Scholar
• Regev R, Katzir H, Yeheskely-Hayon D, et al. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. Febs J. 2007;274(23):6204–6214.
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Döring F, Eynott PR, et al. Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1. Am J Physiol Gastrointest Liver Physiol. 2001;281(3):G697–704.
   PubMed Web of Science ®Google Scholar
• Terao T, Matsuda K, Shouji H. Improvement in site-specific intestinal absorption of furosemide by Eudragit L100–55. J Pharm Pharmacol. 2001;53(4):433–440.
   PubMed Web of Science ®Google Scholar
• Worland PJ, Drummer OH, Jarrott B. Gastric and intestinal absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid. J Pharm Sci. 1984;73(12):1755–1758.
   PubMed Web of Science ®Google Scholar
• Leiper JB. Fate of ingested fluids: factors affecting gastric emptying and intestinal absorption of beverages in humans. Nutrition Rev. 2015;73(Suppl 2):57–72.
   PubMedGoogle Scholar
• Collett A, Higgs NB, Sims E, et al. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999;288(1):171–178.
   PubMed Web of Science ®Google Scholar
• Lemmer HJR, Hamman JH. Paracellular drug absorption enhancement through tight junction modulation. Expert Opin Drug Deliv. 2013;10(1):103–114.
   PubMed Web of Science ®Google Scholar
• Pade V, Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res. 1997;14(9):1210–1215.
   PubMed Web of Science ®Google Scholar
• Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005;315(3):1288–1297.
   PubMed Web of Science ®Google Scholar
• Drewei J, Beglinger C, Kisse T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol. 1992;33(1):39–43.
   PubMed Web of Science ®Google Scholar
• Gramatté T, Oertel R, Terhaag B, et al. Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans. Clin Pharmacol Ther. 1996;59(5):541–549.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency (PMDA). Guideline on drug interactions for drug development and appropriate provision of information; 2019 Feb 08. https://www.pmda.go.jp/files/000228122.pdf
   Google Scholar
• Fritz A, Busch D, Lapczuk J, et al. Expression of clinically relevant drug-metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: an intra-subject analysis. Basic Clin Pharmacol Toxicol. 2019;124(3):245–255.
   PubMed Web of Science ®Google Scholar
• Brussee JM, Yu H, Krekels EHJ, et al. Characterization of intestinal and hepatic CYP3A-mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach. Pharm Res. 2018;35(9):182.
   PubMed Web of Science ®Google Scholar
• Yau E, Petersson C, Dolgos H, et al. A comparative evaluation of models to predict human intestinal metabolism from nonclinical data. Biopharm Drug Dispos. 2017;38(3):163–186.
   PubMed Web of Science ®Google Scholar
• Jones CR, Hatley OJD, Ungell AL, et al. Gut wall metabolism. Application of pre-clinical models for the prediction of human drug absorption and first-pass elimination. Aaps J. 2016;18(3):589–604.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry: food-effect bioavailability and fed bioequivalence studies; December 2002. https://www.fda.gov/media/70945/download.
   Google Scholar
• Levy G, Jusko WJ. Factors affecting the absorption of riboflavin in man. J Pharm Sci. 1966;55(3):285–289.
   PubMed Web of Science ®Google Scholar
• Yuasa H, Inoue K, Hayashi Y. Molecular and functional characteristics of proton-coupled folate transporter. J Pharm Sci. 2009;98(5):1608–1616.
   PubMed Web of Science ®Google Scholar
• Yokooji T, Mori N, Murakami T. Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2009;61(7):911–918.
   PubMed Web of Science ®Google Scholar
• Ladas SD, Isaacs PE, Murphy GM, et al. Comparison of the effects of medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal function in normal man. Gut. 1984;25(4):405–411.
   PubMed Web of Science ®Google Scholar
• Marciani L, Cox EF, Hoad CL, et al. Effects of various food ingredients on gall bladder emptying. Eur J Clin Nutr. 2013;67(11):1182–1187.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Tanabe S, Suzuki T. High-fat diet-induced intestinal hyperpermeability is associated with increased bile acids in the large intestine of mice. J Food Sci. 2016;81(1):H216–222.
   PubMed Web of Science ®Google Scholar
• Russell TL, Berardi RR, Barnett JL, et al. Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm Res. 1993;10(2):187–196.
   PubMed Web of Science ®Google Scholar
• Charman WN, Porter CJ, Mithani S, et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86(3):269–282.
   PubMed Web of Science ®Google Scholar
• Ace LN, Jaffe JM, Kunka RL. Effect of food and an antacid on quinidine bioavailability. Biopharm Drug Dispos. 1983;4(2):183–190.
   PubMed Web of Science ®Google Scholar
• Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36(4):423–426.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46(2):147–150.
   PubMed Web of Science ®Google Scholar
• Lelawongs P, Barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm. 1988;7(3):228–235.
   PubMedGoogle Scholar
• Elvang PA, Hinna AH, Brouwers J, et al. Bile salt micelles and phospholipid vesicles present in simulated and human intestinal fluids: structural analysis by flow field-flow fractionation/multiangle laser light scattering. J Pharm Sci. 2016;105(9):2832–2839.
   PubMed Web of Science ®Google Scholar
• Singh BN. A quantitative approach to probe the dependence and correlation of food‐effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate‐release formulations. Drug Dev Res. 2005;65(2):55–75.
   Web of Science ®Google Scholar
• Omachi F, Kaneko M, Iijima R, et al. Relationship between the effects of food on the pharmacokinetics of oral antineoplastic drugs and their physicochemical properties. J Pharm Health Care Sci. 2019;5(1):26.
   PubMed Web of Science ®Google Scholar
• Saitoh H, Saikachi Y, Kobayashi M, et al. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur J Pharm Sci. 2006;28(1–2):34–42.
   PubMed Web of Science ®Google Scholar
• Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol. 2001;41(2):176–182.
   PubMed Web of Science ®Google Scholar
• Bekersky I, Dressler D, Mekki QA. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol. 2001;41(3):289–297.
   PubMed Web of Science ®Google Scholar
• Kimikawa M, Kamoya K, Toma H, et al. Effective oral administration of tacrolimus in renal transplant recipients. Clin transplant. 2001;15(5):324–329.
   PubMed Web of Science ®Google Scholar
• Tsunashima D, Kawamura A, Murakami M, et al. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study. Clin Ther. 2014;36(5):748–759.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. 2002;22(2):154–159.
   PubMed Web of Science ®Google Scholar
• Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol. 2002;42(4):419–427.
   PubMed Web of Science ®Google Scholar
• Dressor GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71(1):11–20.
   PubMed Web of Science ®Google Scholar
• Radwan A, Amidon GL, Langguth P. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity. Biopharm Drug Dispos. 2012;33(7):403–416.
   PubMed Web of Science ®Google Scholar
• Heinen CA, Reuss S, Amidon GL, et al. Ion pairing with bile salts modulates intestinal permeability and contributes to food-drug interaction of BCS class III compound trospium chloride. Mol Pharm. 2013;10(11):3989–3996.
   PubMedGoogle Scholar
• Bodemar G, Norlander B, Fransson L, et al. The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine–studies in patients with peptic ulcer disease. Br J Clin Pharmacol. 1979;7(1):23–31.
   PubMed Web of Science ®Google Scholar
• Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet. 1983;8(6):463–495.
   PubMed Web of Science ®Google Scholar
• Desmond PV, Harman PJ, Gannoulis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. J Pharm Pharmacol. 1990;42(5):352–354.
   PubMed Web of Science ®Google Scholar
• Holmstock N, Bruyn TD, Bevernage J, et al. Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. Eur J Pharm Sci. 2013;49(1):27–32.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Dunn C, Khadra I, et al. Statistical investigation of simulated fed intestinal media composition on the equilibrium solubility of oral drugs. Eur J Pharm Sci. 2017;99:95–104.
   PubMed Web of Science ®Google Scholar
• Fuchs A, Leigh M, Kloefer B, et al. Advances in the design of fasted state simulating intestinal fluids: faSSIF-V3. Eur J Pharm Biopharm. 2015;94:229–240.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Berardi RR, Dermentzoglou LC, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7):756–761.
   PubMed Web of Science ®Google Scholar
• Mudie DM, Murray K, Hoad CL, et al. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11(9):3039–3047.
   PubMed Web of Science ®Google Scholar
• Yu H, Xia D, Zhu Q, et al. Supersaturated polymeric micelles for oral cyclosporine A delivery. Eur J Pharm Biopharm. 2013;85(3Pt B):1325–1336.
   PubMedGoogle Scholar
• Patel D, Bertz R, Ren S, et al. A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications. Clin Pharmacokinet. 2020;59(4):447–462.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Rekersbrink S, Klotz U, et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(6):551–557.
   PubMed Web of Science ®Google Scholar
• Abeele JVD, Brouwers J, Mattheus R, et al. Gastrointestinal behavior of weakly acidic BCS Class II drugs in man - case study of diclofenac potassium. J Pharm Sci. 2016;105(2):687–696.
   PubMed Web of Science ®Google Scholar
• Karamanolis G, Theofanidou I, Yiasemidou M. A glass of water immediately increases gastric pH in healthy subjects. Dig Dis Sci. 2008;53(12):3128–3132.
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616–2620.
   PubMed Web of Science ®Google Scholar
• Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60(8):531–539.
   PubMed Web of Science ®Google Scholar
• Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, et al. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201–206.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Hamilton CD, Drew RH, et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51(2):453–457.
   PubMed Web of Science ®Google Scholar
• Abuhelwa AY, Mudge S, Upton RN. Mechanistic assessment of the effect of omeprazole on the in vivo pharmacokinetics of itraconazole in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2019;44(2):201–215.
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54(2):159–161.
   PubMed Web of Science ®Google Scholar
• Mori N, Iwamoto H, Yokooji T, et al. Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats. Pharmazie. 2012;67(5):384–388.
   PubMed Web of Science ®Google Scholar
• Kletzl H, Giraudon M, Ducray PS, et al. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine. Anticancer Drugs. 2015;26(5):565–572.
   PubMed Web of Science ®Google Scholar
• Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51(3):958–961.
   PubMed Web of Science ®Google Scholar
• Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev. 2017;6(6):614–626.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293–1302.
   PubMed Web of Science ®Google Scholar
• Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671–1675.
   PubMed Web of Science ®Google Scholar
• Walravens J, Brouwers J, Spriet I, et al. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50(11):725–734.
   PubMed Web of Science ®Google Scholar
• Van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309–1314.
   PubMed Web of Science ®Google Scholar
• Van Seyen M, Colbers A, Abbink EJ, et al. Concomitant intake of Coca-Cola to manage the drug-drug interaction between velpatasvir and omeprazole studied in healthy volunteers. Clin Pharmacol Ther. 2019;106(5):1093–1098.
   PubMed Web of Science ®Google Scholar
• Knoebel RW, Larson RA. Pepsi® or Coke®? Influence of acid on dasatinib absorption. J Oncol Pharm Pract. 2018;24(2):156–158.
   PubMed Web of Science ®Google Scholar
• Reddy A, Norris DF, Momeni SS, et al. The pH of beverages in the United States. J Am Dent Assoc. 2016;147(4):255–263.
   PubMed Web of Science ®Google Scholar
• Khalil SA, Daabis NA, Naggar VF, et al. The in vitro adsorption of some antibiotics on antacids. Pharmazie. 1976;31(2):105–109.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs. 1976;11(1):45–54.
   PubMed Web of Science ®Google Scholar
• Schrickx J, Fink-Gremmels J. P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model. J Vet Pharmacol Ther. 2007;30(1):25–31.
   PubMed Web of Science ®Google Scholar
• Zadeh BSM, Esfahani G, Salimi A. Permeability of ciprofloxacin-loaded polymeric micelles including ginsenoside as P-glycoprotein inhibitor through a Caco-2 cells monolayer as an intestinal absorption model. Molecules. 2018;23(8):1904.
   Web of Science ®Google Scholar
• Nix DE, Watson WA, Lener ME. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989;46(6):700–705.
   PubMed Web of Science ®Google Scholar
• Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36(4):830–832.
   PubMed Web of Science ®Google Scholar
• Neuhofel AL, Wilton JH, Victory JM, et al. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42(4):461–466.
   PubMed Web of Science ®Google Scholar
• Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010;70(5):645–655.
   PubMed Web of Science ®Google Scholar
• Miyata K, Ohtani H, Tsujimoto M, et al. Antacid interaction with new quinolones: dose regimen recommendations based on pharmacokinetic modeling of clinical data for ciprofloxacin, gatifloxacin and norfloxacin and metal cations. Int J Clin Pharmacol Ther. 2007;45(1):63–70.
   PubMed Web of Science ®Google Scholar
• Rubbens J, Brouwers J, Tack J, et al. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. Eur J Pharm Biopharm. 2016;109:122–129.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kawakami A, Nanimatsu A, et al. In vivo evaluation of supersaturation/precipitation/re-dissolution behavior of cinnarizine, a lipophilic weak base, in the gastrointestinal tract: the key process of oral absorption. Eur J Pharm Sci. 2017;96:464–471.
   PubMed Web of Science ®Google Scholar
• Psachoulias D, Vertzoni M, Goumas K, et al. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res. 2011;28(12):3145–3158.
   PubMed Web of Science ®Google Scholar
• Riethorst D, Mols R, Duchateau G, et al. Characterization of human duodenal fluids in fasted and fed state conditions. J Pharm Sci. 2016;105(2):673–681.
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Yeap YY, et al. Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway. Pharm Res. 2013;30(12):2976–2992.
   PubMed Web of Science ®Google Scholar
• Gigliobianco MR, Casadidio C, Censi R, et al. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018;10(3):134.
   PubMed Web of Science ®Google Scholar
• Sun J, Wang F, Sui Y, et al. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals. Int J Nanomedicine. 2012;7:5733–5744.
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim JS, Park HJ, et al. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997–3009.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. J Pharm Sci. 2012;101(9):3019–3032.
   PubMed Web of Science ®Google Scholar
• Bodor N, Dandiker Y Oral formulations of cladribine. U.S. Patent 7,888,328. 2011 February 15.
   Google Scholar
• Szejtli J, Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins.Eur. J Pharm Biopharm. 2005;61(3):115–125.
   Google Scholar
• Buchanan CM, Buchanan NL, Edgar KJ, et al. Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations. J Pharm Sci. 2007;96(11):3100–3116.
   PubMed Web of Science ®Google Scholar
• Wang D, Chen G, Ren L. Preparation and characterization of the sulfobutylether-β-cyclodextrin inclusion complex of amiodarone hydrochloride with enhanced oral bioavailability in fasted state. AAPS PharmSciTech. 2017;18(5):1526–1535.
   PubMed Web of Science ®Google Scholar
• Berben P, Mols R, Brouwers J, et al. Gastrointestinal behavior of itraconazole in humans - Part 2: the effect of intraluminal dilution on the performance of a cyclodextrin-based solution. Int J Pharm. 2017;526(1–2):235–243.
   PubMedGoogle Scholar
• Arima H, Yunomae K, Morikawa T, et al. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm Res. 2004;21(4):625–634.
   PubMed Web of Science ®Google Scholar
• He W, Li Y, Zhang R, et al. Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: preparation and in vitro/in vivo evaluation. Int J Pharm. 2014;476(1–2):223–231.
   PubMedGoogle Scholar
• Nekkanti V, Rueda J, Wang Z, et al. Design, characterization, and in vivo pharmacokinetics of tacrolimus proliposomes. AAPS PharmSciTech. 2016;17(5):1019–1029.
   PubMed Web of Science ®Google Scholar
• Bobbala SK, Veerareddy PR. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J Liposome Res. 2012;22(4):285–294.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Y, Chen J, et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm. 2009;376(1–2):153–160.
   PubMed Web of Science ®Google Scholar
• Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine. 2011;6:965–974.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xue A, Zhang C, et al. Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel. Pharmazie. 2016;71(6):320–326.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry ANDAs: pharmaceutical solid polymorphism, chemistry, manufacturing, and controls information, U.S. Department of Health and Human Services Food and Drug Administration; 2007 July. http://www.fda.gov/cder/guidance/index.htm
   Google Scholar
• Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397–404.
   PubMed Web of Science ®Google Scholar
• Rumondor ACF, Dhareshwar SS, Kesisoglou F. Amorphous solid dispersions or prodrugs: complementary strategies to increase drug absorption. J Pharm Sci. 2016;105(9):2498–2508.
   PubMed Web of Science ®Google Scholar
• Metre S, Mukesh S, Samal SK, et al. Enhanced biopharmaceutical performance of rivaroxaban through polymeric amorphous solid dispersion. Mol Pharm. 2018;15(2):652–668.
   PubMed Web of Science ®Google Scholar
• Kasten G, Lobo L, Dengale S, et al. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine. Eur J Pharm Biopharm. 2018;132:192–199.
   PubMed Web of Science ®Google Scholar
• Huang R, Han J, Wang R, et al. Surfactant-free solid dispersion of BCS class IV drug in an amorphous chitosan oligosaccharide matrix for concomitant dissolution in vitro - permeability increase. Eur J Pharm Sci. 2019;130:147–155.
   PubMed Web of Science ®Google Scholar
• Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603–616.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Sugihara M, Kawakami A, et al. In vivo analysis of supersaturation/precipitation/absorption behavior after oral administration of pioglitazone hydrochloride salt; determinant site of oral absorption. Eur J Pharm Sci. 2017;106:431–438.
   PubMed Web of Science ®Google Scholar
• Seo JH, Park JB, Choi WK, et al. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate. Drug Des Devel Ther. 2015;9:3961–2968. DOI: 10.2147/DDDT.S87687. Abdelkader H, Fathalla Z. Investigation into the emerging role of the basic amino acid L-lysine in enhancing solubility and permeability of BCS Class II and BCS class IV drugs. Pharm Res. 2018;35(8):160.
   PubMed Web of Science ®Google Scholar
• Hisada N, Takano R, Takata N, et al. Characterizing the dissolution profiles of supersaturable salts, cocrystals, and solvates to enhance in vivo oral absorption. Eur J Pharm Biopharm. 2016;103:192–199.
   PubMed Web of Science ®Google Scholar
• Terebetski JL, Cummings JJ, Fauty SE, et al. Combined use of crystalline sodium salt and polymeric precipitation inhibitors to improve pharmacokinetic profile of ibuprofen through supersaturation. AAPS PharmSciTech. 2014;15(5):1334–1344.
   PubMed Web of Science ®Google Scholar
• Bodor N. Novel approaches in prodrug design. Drugs Future. 1981;6(3):165–182.
   Google Scholar
• Bodor N. Prodrugs vs. soft drugs. Amsterdam, The Netherlands: Elsevier Science Publishers B. V.; 1985. 333–354. Chapter in Design of Prodrugs, Bundgaard H. ed.
   Google Scholar
• Bodor N, Kaminski J Prodrugs and site-specific chemical delivery systems. Chapter 30 in Ann. Reports in Med. Chem., 22, Bailey D, ed. Academic Press; 1987. pp 303–313.
   Google Scholar
• Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev. 2007;59(7):677–694.
   PubMed Web of Science ®Google Scholar
• Jain R, Duvvuri S, Kansara V, et al. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int J Pharm. 2007;336(2):233–240.
   PubMedGoogle Scholar
• Agarwal S, Boddu SH, Jain R, et al. Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm. 2008;359(1–2):7–14.
   PubMed Web of Science ®Google Scholar
• Patel M, Sheng Y, Mandava NK. Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir. Int J Pharm. 2014;476(1–2):99–107.
   PubMedGoogle Scholar
• Stappaerts J, Annaert P, Augustijns P. Site dependent intestinal absorption of darunavir and its interaction with ketoconazole. Eur J Pharm Sci. 2013;49(1):51–56.
   PubMed Web of Science ®Google Scholar
• Savla R, Browne J, Plassat V, et al. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Develop Ind Pharm. 2017;43(11):1743–1758.
   PubMed Web of Science ®Google Scholar
• Yeap YY, Trevaskis NL, Quach T, et al. Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation. Mol Pharm. 2013;10(5):1874–1889.
   PubMedGoogle Scholar
• Crum MF, Trevaskis NL, Pouton CW, et al. Transient supersaturation supports drug absorption from lipid-based formulations for short periods of time, but ongoing solubilization is required for longer absorption periods. Mol Pharm. 2017;14(2):394–405.
   PubMedGoogle Scholar
• Santhosh Kumar R, Sureshkumar RA. Review on precipitation inhibitors in supersaturable self emulsifying drug delivery system. J Pharm Sci Res. 2019;11(3):859–868.
   Google Scholar
• Chen Y, Chen C, Zheng J, et al. Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Biol Pharm Bull. 2011;34(2):278–286.
   PubMed Web of Science ®Google Scholar
• Gao P, Rush BD, Pfund WP, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 2003;92(12):2386–2398.
   PubMed Web of Science ®Google Scholar
• Quan G, Niu B, Singh V, et al. Supersaturable solid self-microemulsifying drug delivery system: precipitation inhibition and bioavailability enhancement. Int J Nanomedicine. 2017;12:8801–8811.
   PubMed Web of Science ®Google Scholar
• Woo JS, Song YK, Hong JY, et al. Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci. 2008;33(2):159–165.
   PubMed Web of Science ®Google Scholar
• Han SD, Jung SW, Jang SW, et al. Reduced food-effect on intestinal absorption of dronedarone by self-microemulsifying drug delivery system (SMEDDS). Biol Pharm Bull. 2015;38(7):1026–1032.
   PubMed Web of Science ®Google Scholar
• Basalious EB, Abdallah Ahmed M. Phospholipid based self-nanoemulsifying self-nanosuspension (p-SNESNS) as a dual solubilization approach for development of formulation with diminished food effect: fast/fed in vivo pharmacokinetics study in human. Eur J Pharm Sci. 2017;109:244–252.
   PubMed Web of Science ®Google Scholar
• Yáñez JA, Stephen WJ, Wang SWJ, et al. Intestinal lymphatic transport for drug delivery. Adv Drug Del Rev. 2011;63:923–942.
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Domb AJ, Hoffman A. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opin Drug Deliv. 2015;12(7):1121–1133.
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Almurisi SH, Dukhan AHM, et al. Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view. Drug Deliv. 2016;23(9):3639–3652.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26(5):394–404.
   PubMed Web of Science ®Google Scholar
• Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci. 1998;87(2):164–169.
   PubMed Web of Science ®Google Scholar
• Iwanaga K, Kushibiki T, Miyazaki M, et al. Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs. Biol Pharm Bull. 2006;29(3):508–512.
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Porter CJH, Charman WN. Bile increases intestinal lymphatic drug transport in the fasted rat. Pharm Res. 2005;22(11):1863–1870.
   PubMed Web of Science ®Google Scholar
• Aaa -A-A, Steffansen B, Holm R, et al. Nonionic surfactants increase digoxin absorption in Caco-2 and MDCKII MDR1 cells: impact on P-glycoprotein inhibition, barrier function, and repeated cellular exposure. Int J Pharm. 2018;551(1–2):270–280.
   PubMedGoogle Scholar
• Varma MVS, Panchagnula R. pH-Dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ. J Pharm Sci. 2005;94(12):2632–2643.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Fujii Y, Tabata F, et al. Profiling and trend analysis of food effects on oral drug absorption considering micelle interaction and solubilization by bile micelle. Drug Metab Pharmacokinet. 2011;26(2):180–191.
   PubMed Web of Science ®Google Scholar
• Welling PG, Huang H, Koch PA, et al. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci. 1977;66(4):549–552.
   PubMed Web of Science ®Google Scholar
• Gaginella TS, Bass P, Perrin JH, et al. Effect of bile salts on partitioning behavior and GI absorption of a quaternary ammonium compound, isopropamide iodide. J Pharm Sci. 1973;62(7):1121–1125.
   PubMed Web of Science ®Google Scholar
• Teleki A, Nylander O, Bergström CAS. Intrinsic dissolution rate profiling of poorly water-soluble compounds in biorelevant dissolution media. Pharmaceutics. 2020;12(6):493.
   Web of Science ®Google Scholar
• Park H, Ha E-S, Kim MS. Current status of supersaturable self-emulsifying drug delivery systems. Pharmaceutics. 2020;12(4):365.
   PubMed Web of Science ®Google Scholar
• Yamada H, Yamamoto R. Biopharmaceutical studies on factors affecting rate of absorption of drugs. I. Absorption of salicylamide in micellar solution. Chem Pharm Bull. 1965;13(11):1279–1284.
   PubMed Web of Science ®Google Scholar
• Kimura T, Inui K, Sezaki H. Differences in effects on drug absorption between dihydroxy and trihydroxy bile salts. J Pharmacobiodyn. 1985;8(7):578–585.
   PubMedGoogle Scholar
• Larsen AT, Ohlsson AG, Polentarutti B, et al. Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci. 2013;48(1–2):339–350.
   PubMed Web of Science ®Google Scholar